Audit of community-based anticoagulant monitoring in patients with thromboembolic disease: Is frequent testing necessary?

Internal Medicine Journal

Volumn 34, Issue 11, 2004, Pages 639-641

  Young, L ^a   Ockelford, P ^a   Harper, Paul ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Anticoagulant therapy; Audit; INR; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; COMMUNITY CARE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL SERVICE; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; SELF MONITORING; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COMMUNITY HEALTH SERVICES; DRUG MONITORING; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROGRAM EVALUATION; THROMBOEMBOLISM; WARFARIN;

EID: 9744278991     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00690.x     Document Type: Article

References (7)

1. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003; 123: 499-503.
2. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160: 967-73.
3. British Committee for Standards in Haematology Thrombosis and Haemostasis Task Force. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101: 374-87.
4. Rose P. Audit of anticoagulation therapy. J Clin Pathol 1996; 49: 5-9.
5. Fitzmaurice DASJ, Machin H, British Society of Haematology Task Force for Haemostasis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. BMJ 2001; 323: 985-9.
6. Lidstone V, Janes S, Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haem 2000; 22: 291-3.
7. Horskotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolys 1998; 5: 19-24.